|  |
| --- |
| **Supplementary Figure 1** Characteristics of included studies |
| Publi-cation Year | First author | Country | Number of Centers | Criteria for FD | Most prevalent FD | Mean Age | Female (%) | Prokinetic | Comparator | Rx. durati-on | Comments |
| 1995 | Al-Quorain | Saudi Arabia | 1 | Compatible with Rome | Unclear | 32.5 ±8.5 vs. 33.7 ± 6.8 | 49.4% | Cisapride 5 mg t.i.d. | Placebo | 4 weeks |  |
| 2004 | Amarapurkar | India | 1 | Compatible with Rome | Unclear | 45.2±13.1 vs. 39.8±10.8 | 50% | Itopride hydrochloride 50 mg t.i.d. | Mosapride citrate 5 mg t.i.d. | 2 weeks |  |
| 1997 | Champion | Canada | 6 | Compatible with Rome | Unclear | 40.8 ±40 vs. 41.5 | 69.1% | Cisapride 10-20 mg t.i.d. | Placebo | 6 weeks |  |
| 2004 | Chen | China | 6 | Compatible with Rome | Both | 44 ±12 vs. 43 ± 13 | 53.2% | Mosapride 5 mg t.i.d. | Domperidone 10 mg t.i.d. | 4 weeks | Published in Chinese |
| 2015 | Choi | Korea | 18 | Modified Rome II | Both | 41.3±13.4 vs.  40.3 ± 14 | 69.65% | DA-9701 (Motilitone) 30 mg t.i.d. | Itopride 50 mg t.i.d. | 4 weeks |  |
| 1997 | De Groot | The Netherlands | 1 | Compatible with Rome | Both | 40.9 vs. 43.9 | 54.1% | Cisapride 10 mg t.i.d. | placebo | 4 weeks |  |
| 1989 | De Nutte | Belgium | 1 | Compatible with Rome | EPS | 41±23 | 37.5% | Cisapride 5 mg t.i.d. | placebo | 4 weeks |  |
| 2014 | Du | China | 13 | Rome III | PDS | 43.7±11.9 vs. 41.3 ± 12 | 59.7% | Cinitapride hydrogen tartrate 1 mg t.i.d. | Domperidone 10 mg t.i.d. | 4 weeks |  |
| Publi-cation Year | First author | Country | Number of Centers | Criteria for FD | Most prevalent FD | Mean Age | Female (%) | Prokinetic | Comparator | Rx. durati-on | Comments |
| 1987 | Francois | Belgium | 1 | Compatible with Rome | Both | Not reported | 71% | Cisapride 5-10 mg t.i.d. | placebo | 3 weeks |  |
| 2002 | Hallerback | Denmark, Germany, France, Sweden and the UK | 79 | Compatible with Rome | Both | Not reported | 64% | Mosapride 5 mg b.i.d., 10 mg b.i.d., 7.5 mg t.i.d. | placebo | 6 weeks |  |
| 1998 | Hansen | Denmark | 1 | Compatible with Rome | Both | 43 ±15 vs.42± 14 | 68% | Cisapride 10 mg t.i.d. | placebo | 2 weeks |  |
| 2002 | Holtmann | Germany and Australia | 16 | Compatible with Rome | Both | 50 ±14.3 vs. 51.8± 13 | 48.3% | Cisapride 10 mg t.i.d. | placebo | 8 weeks |  |
| 2006 | Holtmann | Germany | 79 | Rome II | Both | 47.8±16.1 vs. 49.3±15.5 | 63.5% | Itopride 50 mg t.i.d., 100 mg t.i.d., and 200 mg t.i.d. | placebo | 8 weeks |  |
| 1995 | Kellow | Australia | 1 | Compatible with Rome | Both | 50 ±18 vs. 46± 15 | 70.5% | Cisapride 10 mg t.i.d. | placebo | 4 weeks |  |
| 2012 | Kusunoki | Japan | 1 | Rome II | Both | 40.3±13.2 vs 40.6 ±18 | 65% | Acotiamide 100 mg t.i.d. | placebo | 14-18 days |  |
| 2005 | Li | China | Unclear | Compatible with Rome | PDS | 38 | 53% | Itopride 50mg t.i.d. | Domperidone 10mg t.i.d. | 4 weeks | Published in Chinese |
| Publi-cation Year | First author | Country | Number of Centers | Criteria for FD | Most prevalent FD | Mean Age | Female (%) | Prokinetic | Comparator | Rx. durati-on | Comments |
| 2009 | Lin | China | 1 | Rome III | PDS | 41 vs. 40 | 67% | Mosapride dispersible 50mg t.i.d. | placebo | 2 weeks | Published in Chinese |
| 2010 | Ma | China | 8 | Rome III | Both | 36.2±13.9 vs. 36.8±13.1 | 70% | Itopride 50 mg t.i.d. | Sham acupuncture | 4 weeks |  |
| 2010\_1 | Matsueda | Japan | 33 | Rome II | Both | N/A vs. 37.3±10.2 | 56.2% | Acotiamide 100 mg or 300 mg t.i.d. | placebo | 4 weeks |  |
| 2010\_2 | Matsueda | Japan | 46 | Rome II | PDS | N/A vs. 30.8±13.1 | 65.4% | Acotiamide 50, 100 or 300 mg t.i.d. | placebo | 4 weeks |  |
| 2012 | Matsueda | Japan | 67 | Room III | PDS | 37.6±10.7 vs.37.1±9.9 | 59.3% | Acotiamide 100 mg t.i.d. | placebo | 4 weeks |  |
| 2003 | Mo | China | 4 | Rome II | PDS | 48.79 vs. 47.39 | 64% | Itopride hydrochloride 50mg t.i.d. | Domperidone 10mg t.i.d. | 2 weeks | Published in Chinese |
| 1987 | Rosch | Germany | 1 | Compatible with Rome | Both | Not reported | Not reported | Cisapride 10 mg t.i.d. | placebo | 4 weeks |  |
| 2014 | Shen | China | 1 | Rome III | PDS | 57.42 vs. 64.17 ( p>0.05) | 41% | Itopride 1 tablet t.i.d. | placebo | 2 weeks | Published in Chinese |
| 2003 | Sun | China | 4 | Compatible with Rome | PDS | Not reported | Not reported | Itopride hydrochloride 50mg t.i.d. | Domperidone 10mg t.i.d. | 2 weeks | Published in Chinese |
| Publi-cation Year | First author | Country | Number of Centers | Criteria for FD | Most prevalent FD | Mean Age | Female (%) | Prokinetic | Comparator | Rx. durati-on | Comments |
| 2011 | Tack | US, Japan and Europe | Multi-center | Rome II | PDS | Not reported | Not reported | Acotiamide 100 or 300 mg t.i.d. | placebo | 12 weeks | Conference abstract |
| 2000 | Talley | France, the Netherlands, Germany, Austria, the USA and Canada | Multi-center | Compatible with Rome | Both | 46.3 vs. 46.1 | 69% | ABT-229 1.25, 2.5,5 or 10 mg b.i.d. | placebo | 4 weeks |  |
| 2008 | Talley | Not reported | Not reported | Rome II | Both | Not reported | Not reported | Acotiamide 300, 600 and 900 mg t.i.d. | placebo | 12 weeks | Conference abstract |
| 2008\_1 | Talley | Germany, France, The Netherlands, Belgium, Poland, UK, USA and Canada | 170 | Rome II | Both | 42.9±12.9 vs. 43.3±12.9 | 64.7% | Itopride 100 mg t.i.d. | placebo | 8 weeks |  |
| 2008\_2 | Talley | USA, Canada, Poland, Germany | Multi-center | Rome II | Both | 42.6±12.8 vs. 43 ±12.5 | 67.2% | Itopride 100 mg t.i.d. | placebo | 8 weeks |  |
| 2000 | Teixeira | Portugal | 1 | Rome II | Unclear | Median 39 | 71% | Cisapride 10 mg t.i.d. | placebo | 15 days | Published in Portuguese |
| Publi-cation Year | First author | Country | Number of Centers | Criteria for FD | Most prevalent FD | Mean Age | Female (%) | Prokinetic | Comparator | Rx. durati-on | Comments |
| 2008\_1 | Vakil | the USA, UK, Canada and South Africa | Multi-center, 675 sites | Rome II | PDS | 47.3±13.2 vs.44.2±14.5 | 100% | Tegaserod 6 mg b.i.d. | placebo | 6 weeks |  |
| 2008\_2 | Vakil | the USA, UK, Canada and South Africa | Multi-center, 675 sites | Rome II | PDS | 43.4±13.7 vs. 43.6±13.2 | 100% | Tegaserod 6 mg b.i.d. | placebo | 6 weeks |  |
| 1995 | Wang | China | 16 | Compatible with Rome | PDS | 43 vs 41 | 54% | Cisapride 5mg t.i.d. | placebo | 4 weeks | Published in Chinese |
| 2014 | Wong | Malaysia | 1 | Compatible with Rome | PDS | Not reported | Not reported | Itopride 100 mg t.i.d. | placebo | 8 weeks | Conference abstract |
| 1997 | Yeoh | Singapore | 1 | Compatible with Rome | Both | Not reported | 53% | Cisapride 10 mg t.i.d. | placebo | 4 weeks |  |
| 2000 | Zhou | China | 5 | Compatible with Rome | PDS | 45.8 vs 42.6 | 64% | Itopride hydrochloride 50mg t.i.d. | Domperidone 10mg t.i.d. | 2 weeks | Published in Chinese |
| 2005 | Zhu | China | Multi-center | Compatible with Rome | PDS | Not reported | Not reported | Itopride 50mg t.i.d. | Domperidone 10mg t.i.d. | 4 weeks | Published in Chinese |

\*FD; Functional dyspepsia, Rx.;Treatment, EPS; Epigastric pain syndrome, PDS; Post-prandial distress syndrome